Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $65.2B | $31.7B | $20.6B | $6.0B | 77.8% | 44.7% | 94.9% |
| 2024 | $45.0B | $18.8B | $10.6B | $414M | 74.2% | 32.0% | 102.1% |
| 2023 | $34.1B | $11.9B | $5.2B | $-3.2B | 48.6% | 19.6% | -16.1% |
| 2022 | $28.5B | $8.7B | $6.2B | $4.6B | 58.6% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 28,541.40 | 34,124 | 45,043 | 65,179 |
| Operating Revenue | - | 28,541.40 | 34,124 | 45,043 | 65,179 |
| Cost Of Revenue | - | 6,629.80 | 7,082 | 8,418 | 11,052 |
| Gross Profit | - | 21,911.60 | 27,042 | 36,625 | 54,127 |
| Operating Expense | - | 13,631.20 | 16,717 | 19,585 | 24,431 |
| Research And Development | - | 7,190.80 | 9,313 | 10,991 | 13,337 |
| Selling General And Administration | - | 6,440.40 | 7,404 | 8,594 | 11,094 |
| Total Expenses | - | 20,261 | 23,799 | 28,003 | 35,483 |
| Operating Income | - | 8,280.40 | 10,325 | 17,040 | 29,696 |
| EBITDA | - | 8,660.50 | 11,852 | 18,807 | 31,693 |
| Normalized EBITDA | - | 10,224.30 | 15,720 | 22,948 | 35,087 |
| EBIT | - | 7,138 | 10,325 | 17,040 | 29,696 |
| Interest Income | 25.40 | 62.80 | 173.60 | 175.20 | - |
| Interest Expense | 339.80 | 331.60 | 485.90 | 780.60 | - |
| Net Interest Income | -314.40 | -268.80 | -312.30 | -605.40 | - |
| Other Non Operating Income Expenses | - | 358.60 | 97 | -219 | -571 |
| Other Income Expense | - | -1,205.20 | -3,771 | -4,360 | -3,965 |
| Interest Income Non Operating | 25.40 | 62.80 | 173.60 | 175.20 | - |
| Interest Expense Non Operating | 339.80 | 331.60 | 485.90 | 780.60 | - |
| Net Non Operating Interest Income Expense | -314.40 | -268.80 | -312.30 | -605.40 | - |
| Pretax Income | - | 6,806.40 | 6,554 | 12,680 | 25,731 |
| Tax Provision | - | 561.60 | 1,314 | 2,090 | 5,091 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -129.80 | -777.47 | -682.55 | -671.52 |
| Net Income Continuous Operations | - | 6,244.80 | 5,240 | 10,590 | 20,640 |
| Net Income From Continuing And Discontinued Operation | - | 6,244.80 | 5,240 | 10,590 | 20,640 |
| Net Income From Continuing Operation Net Minority Interest | - | 6,244.80 | 5,240 | 10,590 | 20,640 |
| Net Income | - | 6,244.80 | 5,240 | 10,590 | 20,640 |
| Net Income Common Stockholders | - | 6,244.80 | 5,240 | 10,590 | 20,640 |
| Net Income Including Noncontrolling Interests | - | 6,244.80 | 5,240 | 10,590 | 20,640 |
| Normalized Income | - | 7,678.80 | 8,330.53 | 14,048.45 | 23,362.48 |
| Diluted NI Availto Com Stockholders | - | 6,244.80 | 5,240 | 10,590 | 20,640 |
| Basic Average Shares | - | 950.18 | 899.38 | 897.54 | 894.80 |
| Diluted Average Shares | - | 950.18 | 903.28 | 904.06 | 899.30 |
| Reconciled Depreciation | - | 1,522.50 | 1,527 | 1,767 | 1,997 |
| Reconciled Cost Of Revenue | - | 6,629.80 | 7,082 | 8,418 | 11,052 |
| Total Unusual Items | - | -1,563.80 | -3,868 | -4,141 | -3,394 |
| Total Unusual Items Excluding Goodwill | - | -1,563.80 | -3,868 | -4,141 | -3,394 |
| Net Income Discontinuous Operations | 0 | - | - | - | - |
| Special Income Charges | - | -1,153.10 | -3,868 | -4,141 | -3,394 |
| Gain On Sale Of Business | 0 | - | - | - | - |
| Other Special Charges | - | 908.50 | 3,800 | 3,280 | 2,910 |
| Write Off | - | 244.60 | 68 | 861 | 484 |
| Impairment Of Capital Assets | 236.10 | - | - | - | - |
| Restructuring And Mergern Acquisition | - | 23 | 45.50 | 3,280 | 2,910 |
| Gain On Sale Of Security | 176.90 | -410.70 | -20.20 | -49.50 | - |
| General And Administrative Expense | 6,431.60 | 6,440.40 | 7,403.10 | 8,593.80 | - |
| Other Gand A | 6,431.60 | 6,440.40 | 7,403.10 | 8,593.80 | - |
| Salaries And Wages | -289.70 | -372.90 | -461.90 | -461.70 | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Eli Lilly and Companythis co. | LLY | $1.0T | 48.62↑ premium | 37.82 | 77.8% | 32.77 |
| Johnson & Johnson | JNJ | $549.3B | 20.49 | 6.74 | 32.9% | 14.07 |
| AbbVie Inc. | ABBV | $397.4B | 94.94 | - | -128.0% | 26.07 |
| UnitedHealth Group Incorporated | UNH | $360.1B | 29.86 | 3.83 | 12.8% | 17.96 |
| Merck & Co., Inc. | MRK | $297.0B |
| - |
| - |
| - |
| - |
| - |
| - |
| 16.27 |
| 5.65 |
| 34.7% |
| 11.74 |
| Amgen Inc. | AMGN | $186.5B | 24.19 | 21.54 | 89.1% | 13.73 |
| Thermo Fisher Scientific Inc. | TMO | $179.1B | 26.72 | 3.35 | 12.6% | 18.11 |
| Gilead Sciences, Inc. | GILD | $160.4B | 18.85 | 7.06 | 37.5% | 12.94 |
| Abbott Laboratories | ABT | $158.1B | 24.24 | 3.03 | 12.5% | 13.54 |
| Peer Median | - | 24.21 | 5.65 | 22.8% | 13.90 | |
Historically, Jun has averaged the highest return (+8.7%); Jul the lowest (-2.6%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -3.5%Negative MonthJan 2026: -3.49% | +1.4%Neutral MonthFeb 2026: +1.43% | -12.6%Negative MonthMar 2026: -12.57% | +1.6%Neutral MonthApr 2026: +1.61% | +18.2%Positive MonthMay 2026: +18.23% | +8.5%Positive MonthJun 2026: +8.55% | -4.2%Negative MonthJul 2026: -4.22% | +11.4%*Positive MonthAug 2026: +11.45% | — | — | — | — |
| 2025 | +5.1%Positive MonthJan 2025: +5.06% | +13.5%Positive MonthFeb 2025: +13.51% | -10.3%Negative MonthMar 2025: -10.29% | +8.8%Positive MonthApr 2025: +8.84% | -17.9%Negative MonthMay 2025: -17.94% | +5.7%Positive MonthJun 2025: +5.67% | -5.1%Negative MonthJul 2025: -5.06% | -1.0%Neutral MonthAug 2025: -1.01% | +4.2%Positive MonthSep 2025: +4.15% | +13.1%Positive MonthOct 2025: +13.09% | +24.6%Positive MonthNov 2025: +24.64% | -0.1%Neutral MonthDec 2025: -0.07% |
| 2024 | +10.8%Positive MonthJan 2024: +10.75% | +16.7%Positive MonthFeb 2024: +16.74% | +3.2%Positive MonthMar 2024: +3.22% | +0.4%Neutral MonthApr 2024: +0.40% | +5.0%Positive MonthMay 2024: +5.02% | +10.4%Positive MonthJun 2024: +10.37% | -11.2%Negative MonthJul 2024: -11.17% | +19.4%Positive MonthAug 2024: +19.37% | -7.7%Negative MonthSep 2024: -7.72% | -6.3%Negative MonthOct 2024: -6.34% | -4.1%Negative MonthNov 2024: -4.14% | -2.9%Negative MonthDec 2024: -2.94% |
| 2023 | -5.9%Negative MonthJan 2023: -5.93% | -9.6%Negative MonthFeb 2023: -9.57% | +10.3%Positive MonthMar 2023: +10.35% | +15.3%Positive MonthApr 2023: +15.27% | +8.5%Positive MonthMay 2023: +8.49% | +9.2%Positive MonthJun 2023: +9.20% | -3.1%Negative MonthJul 2023: -3.08% | +21.9%Positive MonthAug 2023: +21.92% | -3.1%Negative MonthSep 2023: -3.08% | +3.1%Positive MonthOct 2023: +3.13% | +6.7%Positive MonthNov 2023: +6.70% | -1.4%Neutral MonthDec 2023: -1.37% |
| 2022 | -11.2%Negative MonthJan 2022: -11.16% | +1.9%Neutral MonthFeb 2022: +1.86% | +14.6%Positive MonthMar 2022: +14.57% | +2.0%Positive MonthApr 2022: +2.01% | +7.3%Positive MonthMay 2022: +7.29% | +3.4%Positive MonthJun 2022: +3.44% | +1.7%Neutral MonthJul 2022: +1.68% | -8.6%Negative MonthAug 2022: -8.63% | +7.3%Positive MonthSep 2022: +7.34% | +12.0%Positive MonthOct 2022: +11.98% | +2.5%Positive MonthNov 2022: +2.48% | -1.4%Neutral MonthDec 2022: -1.41% |
| 2021 | — | — | — | — | +9.3%Positive MonthMay 2021: +9.28% | +14.9%Positive MonthJun 2021: +14.91% | +6.1%Positive MonthJul 2021: +6.09% | +6.1%Positive MonthAug 2021: +6.07% | -10.5%Negative MonthSep 2021: -10.55% | +10.3%Positive MonthOct 2021: +10.26% | -2.6%Negative MonthNov 2021: -2.64% | +11.4%Positive MonthDec 2021: +11.36% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
